To help it pursue its development in new markets, Stallergenes is supported by unique expertise and the responsiveness of its structure. In high-potential emerging markets such as Russia, Stallergenes adopts a tailored product offer strategy, working with partners closely involved in the field of respiratory allergy treatment.
In the last five years, five new subsidiaries have been opened in Europe and several partnership agreements have been signed.
Stallergenes is a European biopharmaceutical company dedicated to desensitization therapies for the prevention and treatment of allergy-related respiratory diseases, such as rhinoconjunctivitis and allergic asthma. A pioneer and leader in sublingual desensitization treatments, Stallergenes devotes 21% of its turnover, in gross terms, to Research and Development and is actively involved in the development of a new therapeutic class: sublingual desensitization tablets.
In 2008, Stallergenes had a turnover of 171 million euros and more than 500,000 patients were treated with Stallergenes desensitization products.
Stallergenes is listed on Euronext Paris (Compartment B and is part of the sample composing the SBF 120 index.
ISIN code: FR0000065674 Reuters code: GEN.PA Bloomberg code: GEN.FP Additional information is available athttp://www.stallergenes.com About Solvay Pharmaceuticals
Solvay Pharmaceuticals is a research driven group of companies that
constitutes the global pharmaceutical business of the Solvay Group. These
companies seek to fulfill carefully selected, unmet medical needs in the
therapeutic areas of neuroscience, cardiometabolic, influenza vaccines,
gastroenterology and men's and women's healt
Copyright©2009 PR Newswire.
All rights reserved